In a special report last week, the European Heart Journal spoke to cardiovascular disease (CVD) thought leaders across the globe to gather their insights on the impact of the COVID-19 pandemic on cardiovascular care.
Various healthcare organizations are working to better prepare physicians and advanced practice providers for best practices in providing virtual care.
The pandemic has accelerated the pace of positive change, exposed longstanding racial inequalities that resulted in a disproportionate burden of COVID-19 infection and mortality, and demonstrated new learning needs for health care professionals.
THE RECOVERY TRIAL News emerged from the UK on June 16 around very promising results with dexamethasone in the treatment of COVID-19 infected patients in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial. RECOVERY is a randomized trial investigating whether treatment with either (1)Lopinavir-Ritonavir, (2)Hydroxychloroquine, (3)Corticosteroids, (4)Azithromycin,(5) Convalescent plasma or (6)Tocilizumab prevents death in patients with COVID-19.
A group of Italian researchers recently hypothesized that it is actually the endothelium that is being targeted by the COVID-19 virus.
What defines a misdiagnosis, or a “diagnostic error” in medicine? In 2015, the National Academies of Sciences, Engineering, and Medicine’s “Improving Diagnosis in Health Care” defined a diagnostic error as “the failure to establish an accurate and timely explanation of the patient’s health problem(s) or (b) communicate that explanation to the patient.” This comprehensive report
It was initially thought that perhaps children, when infected with COVID-19, developed milder cases which appear clinically like a minor upper respiratory infection. In late April, however, the first published case of a Kawasaki-like disease associated with COVID-19 was described in Hospital Pediatrics.
To date, several pharmaceutical agents have been evaluated in the treatment of COVID-19. On May 23, the first report of a positive response to a therapeutic agent, remdesivir, was reported in the New England Journal of Medicine. The positive top line results of this trial were shared via a press release a few weeks ago.
Students and teachers across all levels of schooling – elementary through high school to post-secondary education and professional education have changed in light of the COVID-19 pandemic. The physical classroom model has disappeared and may not return in its prior format. To thrive in a remote education world, students and teachers must adapt their learning
COVID-19 does not always fit into the pattern of respiratory illness. While initially unexpected, clinicians and researchers are learning more each day that COVID-19 infection wears many disguises. In some victims, it clearly does not make its initial appearance as a respiratory virus.
Although we will not be placing COVID-19 in our rearview mirror in the foreseeable future, it is already apparent that there will almost certainly be legacies that are actually more positive than negative for the healthcare system at large.
What we are learning about management of COVID-19 infected patients is growing daily. Many clinicians have expressed never having seen anything quite like this; obviously the sheer number of critically ill patients is unprecedented, as is the unique pathophysiology of what occurs in the lungs of COVID patients. The lack of definitive therapies for the